Aaron G Lim1, Josephine G Walker2, Nyashadzaishe Mafirakureva2, Gul Ghuttai Khalid3, Huma Qureshi4, Hassan Mahmood5, Adam Trickey2, Hannah Fraser2, Khawar Aslam3, Gregoire Falq6, Camille Fortas7, Hassaan Zahid3, Ammara Naveed8, Rosa Auat3, Quaid Saeed9, Charlotte F Davies2, Christinah Mukandavire10, Nancy Glass11, David Maman6, Natasha K Martin12, Matthew Hickman2, Margaret T May2, Saeed Hamid13, Anne Loarec6, Francisco Averhoff11, Peter Vickerman2. 1. Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK. Electronic address: aaron.lim@bristol.ac.uk. 2. Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK. 3. Médecins Sans Frontières, Brussels, Belgium. 4. Doctors Plaza, Karachi, Pakistan. 5. Pakistan Health Research Council, Islamabad, Pakistan; WHO, Islamabad, Pakistan. 6. Epicentre, Médecins Sans Frontières, Paris, France. 7. Pasteur Institute, Paris, France. 8. Department of Gastroenterology and Hepatology, Pakistan Kidney and Liver Institute and Research Center, Lahore, Pakistan. 9. National AIDS Control Programme, Islamabad, Pakistan. 10. Department of Infectious Disease Epidemiology, Imperial College London, London, UK. 11. Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA. 12. Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK; Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, CA, USA. 13. Aga Khan University, Karachi, Pakistan.
Abstract
BACKGROUND: The WHO elimination strategy for hepatitis C virus advocates scaling up screening and treatment to reduce global hepatitis C incidence by 80% by 2030, but little is known about how this reduction could be achieved and the costs of doing so. We aimed to evaluate the effects and cost of different strategies to scale up screening and treatment of hepatitis C in Pakistan and determine what is required to meet WHO elimination targets for incidence. METHODS: We adapted a previous model of hepatitis C virus transmission, treatment, and disease progression for Pakistan, calibrating using available data to incorporate a detailed cascade of care for hepatitis C with cost data on diagnostics and hepatitis C treatment. We modelled the effect on various outcomes and costs of alternative scenarios for scaling up screening and hepatitis C treatment in 2018-30. We calibrated the model to country-level demographic data for 1960-2015 (including population growth) and to hepatitis C seroprevalence data from a national survey in 2007-08, surveys among people who inject drugs (PWID), and hepatitis C seroprevalence trends among blood donors. The cascade of care in our model begins with diagnosis of hepatitis C infection through antibody screening and RNA confirmation. Diagnosed individuals are then referred to care and started on treatment, which can result in a sustained virological response (effective cure). We report the median and 95% uncertainty interval (UI) from 1151 modelled runs. FINDINGS: One-time screening of 90% of the 2018 population by 2030, with 80% referral to treatment, was projected to lead to 13·8 million (95% UI 13·4-14·1) individuals being screened and 350 000 (315 000-385 000) treatments started annually, decreasing hepatitis C incidence by 26·5% (22·5-30·7) over 2018-30. Prioritised screening of high prevalence groups (PWID and adults aged ≥30 years) and rescreening (annually for PWID, otherwise every 10 years) are likely to increase the number screened and treated by 46·8% and decrease incidence by 50·8% (95% UI 46·1-55·0). Decreasing hepatitis C incidence by 80% is estimated to require a doubling of the primary screening rate, increasing referral to 90%, rescreening the general population every 5 years, and re-engaging those lost to follow-up every 5 years. This approach could cost US$8·1 billion, reducing to $3·9 billion with lowest costs for diagnostic tests and drugs, including health-care savings, and implementing a simplified treatment algorithm. INTERPRETATION: Pakistan will need to invest about 9·0% of its yearly health expenditure to enable sufficient scale up in screening and treatment to achieve the WHO hepatitis C elimination target of an 80% reduction in incidence by 2030. FUNDING: UNITAID.
BACKGROUND: The WHO elimination strategy for hepatitis C virus advocates scaling up screening and treatment to reduce global hepatitis C incidence by 80% by 2030, but little is known about how this reduction could be achieved and the costs of doing so. We aimed to evaluate the effects and cost of different strategies to scale up screening and treatment of hepatitis C in Pakistan and determine what is required to meet WHO elimination targets for incidence. METHODS: We adapted a previous model of hepatitis C virus transmission, treatment, and disease progression for Pakistan, calibrating using available data to incorporate a detailed cascade of care for hepatitis C with cost data on diagnostics and hepatitis C treatment. We modelled the effect on various outcomes and costs of alternative scenarios for scaling up screening and hepatitis C treatment in 2018-30. We calibrated the model to country-level demographic data for 1960-2015 (including population growth) and to hepatitis C seroprevalence data from a national survey in 2007-08, surveys among people who inject drugs (PWID), and hepatitis C seroprevalence trends among blood donors. The cascade of care in our model begins with diagnosis of hepatitis C infection through antibody screening and RNA confirmation. Diagnosed individuals are then referred to care and started on treatment, which can result in a sustained virological response (effective cure). We report the median and 95% uncertainty interval (UI) from 1151 modelled runs. FINDINGS: One-time screening of 90% of the 2018 population by 2030, with 80% referral to treatment, was projected to lead to 13·8 million (95% UI 13·4-14·1) individuals being screened and 350 000 (315 000-385 000) treatments started annually, decreasing hepatitis C incidence by 26·5% (22·5-30·7) over 2018-30. Prioritised screening of high prevalence groups (PWID and adults aged ≥30 years) and rescreening (annually for PWID, otherwise every 10 years) are likely to increase the number screened and treated by 46·8% and decrease incidence by 50·8% (95% UI 46·1-55·0). Decreasing hepatitis C incidence by 80% is estimated to require a doubling of the primary screening rate, increasing referral to 90%, rescreening the general population every 5 years, and re-engaging those lost to follow-up every 5 years. This approach could cost US$8·1 billion, reducing to $3·9 billion with lowest costs for diagnostic tests and drugs, including health-care savings, and implementing a simplified treatment algorithm. INTERPRETATION: Pakistan will need to invest about 9·0% of its yearly health expenditure to enable sufficient scale up in screening and treatment to achieve the WHO hepatitis C elimination target of an 80% reduction in incidence by 2030. FUNDING: UNITAID.
Authors: A Sibley; K H Han; A Abourached; L A Lesmana; M Makara; W Jafri; R Salupere; A M Assiri; A Goldis; F Abaalkhail; Z Abbas; A Abdou; F Al Braiki; F Al Hosani; K Al Jaberi; M Al Khatry; M A Al Mulla; H Al Quraishi; A Al Rifai; Y Al Serkal; A Alam; S M Alavian; H I Alashgar; S Alawadhi; L Al-Dabal; P Aldins; F Z Alfaleh; A S Alghamdi; R Al-Hakeem; A A Aljumah; A Almessabi; A N Alqutub; K A Alswat; I Altraif; M Alzaabi; N Andrea; M A Babatin; A Baqir; M T Barakat; O M Bergmann; A R Bizri; S Blach; A Chaudhry; M S Choi; T Diab; S Djauzi; E S El Hassan; S El Khoury; C Estes; S Fakhry; J I Farooqi; H Fridjonsdottir; R A Gani; A Ghafoor Khan; L Gheorghe; M Gottfredsson; S Gregorcic; J Gunter; B Hajarizadeh; S Hamid; I Hasan; A Hashim; G Horvath; B Hunyady; R Husni; A Jeruma; J G Jonasson; B Karlsdottir; D Y Kim; Y S Kim; Z Koutoubi; V Liakina; Y S Lim; A Löve; M Maimets; R Malekzadeh; M Matičič; M S Memon; S Merat; J E Mokhbat; F H Mourad; D H Muljono; A Nawaz; N Nugrahini; S Olafsson; S Priohutomo; H Qureshi; P Rassam; H Razavi; D Razavi-Shearer; K Razavi-Shearer; B Rozentale; M Sadik; K Saeed; A Salamat; F M Sanai; A Sanityoso Sulaiman; R A Sayegh; A I Sharara; M Siddiq; A M Siddiqui; G Sigmundsdottir; B Sigurdardottir; D Speiciene; A Sulaiman; M A Sultan; M Taha; J Tanaka; H Tarifi; G Tayyab; I Tolmane; M Ud Din; M Umar; J Valantinas; J Videčnik-Zorman; C Yaghi; E Yunihastuti; M A Yusuf; B F Zuberi; J D Schmelzer Journal: J Viral Hepat Date: 2015-12 Impact factor: 3.728
Authors: Brian R Edlin; Thomas F Kresina; Daniel B Raymond; Michael R Carden; Marc N Gourevitch; Josiah D Rich; Laura W Cheever; Victoria A Cargill Journal: Clin Infect Dis Date: 2005-04-15 Impact factor: 9.079
Authors: Adam Trickey; Margaret T May; Charlotte Davies; Huma Qureshi; Saeed Hamid; Hassan Mahmood; Quaid Saeed; Matthew Hickman; Nancy Glass; Francisco Averhoff; Peter Vickerman Journal: Am J Trop Med Hyg Date: 2017-10-12 Impact factor: 2.345
Authors: Alastair Heffernan; Ella Barber; Nicola A Cook; Asmaa I Gomaa; Yolande X Harley; Christopher R Jones; Aaron G Lim; Zameer Mohamed; Shevanthi Nayagam; Gibril Ndow; Rajiv Shah; Mark W Sonderup; C Wendy Spearman; Imam Waked; Robert J Wilkinson; Simon D Taylor-Robinson Journal: Open Forum Infect Dis Date: 2017-11-17 Impact factor: 3.835
Authors: Yuely A Capileno; Rafael Van den Bergh; Dmytro Donchunk; Sven Gudmund Hinderaker; Saeed Hamid; Rosa Auat; Gul Ghuttai Khalid; Razia Fatima; Aashifa Yaqoob; Catherine Van Overloop Journal: PLoS One Date: 2017-04-27 Impact factor: 3.240
Authors: Aaron G Lim; Huma Qureshi; Hassan Mahmood; Saeed Hamid; Charlotte F Davies; Adam Trickey; Nancy Glass; Quaid Saeed; Hannah Fraser; Josephine G Walker; Christinah Mukandavire; Matthew Hickman; Natasha K Martin; Margaret T May; Francisco Averhoff; Peter Vickerman Journal: Int J Epidemiol Date: 2018-04-01 Impact factor: 7.196
Authors: Aaron G Lim; Nick Scott; Josephine G Walker; Saeed Hamid; Margaret Hellard; Peter Vickerman Journal: PLoS Med Date: 2021-10-19 Impact factor: 11.069
Authors: Mouaddh Abdulmalik Nagi; Mustafa Ali Ali Rezq; Sermsiri Sangroongruangsri; Montarat Thavorncharoensap; Pramitha Esha Nirmala Dewi Journal: Glob Health Res Policy Date: 2022-07-25
Authors: Nyashadzaishe Mafirakureva; Aaron G Lim; Gul Ghuttai Khalid; Khawar Aslam; Linda Campbell; Hassaan Zahid; Rafael Van den Bergh; Gregoire Falq; Camille Fortas; Yves Wailly; Rosa Auat; Dmytro Donchuk; Anne Loarec; Joanna Coast; Peter Vickerman; Josephine G Walker Journal: J Viral Hepat Date: 2020-11-04 Impact factor: 3.728